Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $810.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price hoisted by Royal Bank Of Canada from $737.00 to $810.00 in a research note issued to investors on Thursday morning,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the biopharmaceutical company’s stock.

Other analysts also recently issued reports about the stock. Jefferies Financial Group increased their price target on shares of Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Truist Financial boosted their price objective on shares of Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the stock a “buy” rating in a report on Wednesday. Citigroup upped their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, September 21st. Finally, JPMorgan Chase & Co. increased their target price on shares of Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an “overweight” rating in a research note on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $834.24.

Regeneron Pharmaceuticals Stock Up 0.9%

Shares of REGN stock opened at $746.54 on Thursday. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $859.34. The firm has a market cap of $76.86 billion, a PE ratio of 18.45, a price-to-earnings-growth ratio of 1.40 and a beta of 0.16. The stock has a 50 day moving average of $790.99 and a 200-day moving average of $720.67. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. Regeneron Pharmaceuticals’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the prior year, the business earned $12.81 earnings per share. On average, equities analysts predict that Regeneron Pharmaceuticals will post 47.93 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Insider Activity

In other news, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the transaction, the executive vice president owned 13,134 shares in the company, valued at approximately $11,163,900. This represents a 8.47% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 3,946 shares of company stock worth $3,302,458. 6.97% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $5,682,636,000. State Street Corp lifted its position in shares of Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after buying an additional 170,210 shares during the period. Nuveen LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after buying an additional 835,240 shares during the period. Invesco Ltd. boosted its stake in Regeneron Pharmaceuticals by 7.2% in the 4th quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company’s stock valued at $1,228,127,000 after buying an additional 106,632 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in Regeneron Pharmaceuticals by 8.5% in the 2nd quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company’s stock valued at $805,023,000 after buying an additional 101,469 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.